For the quarter ending 2025-09-30, CRVS had -$11,824K decrease in cash & cash equivalents over the period. -$9,566K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | -10,157 | 7,195 |
| Depreciation and amortization | 28 | 51 |
| Accretion related to marketable securities | 459 | 625 |
| Stock-based compensation | 1,249 | 2,507 |
| Change in fair value of warrant liability | 0 | -27,141 |
| Loss from equity method investment | -323 | -928 |
| Accounts receivable - related party | -54 | 11 |
| Prepaid and other current assets | -64 | -1,081 |
| Operating lease right-of-use assets | -85 | -165 |
| Other assets | 226 | -6 |
| Accounts payable | -1,163 | 555 |
| Accrued and other liabilities | 708 | 1,288 |
| Operating lease liability | -72 | -39 |
| Net cash used in operating activities | -9,566 | -14,040 |
| Purchases of marketable securities | 31,149 | 47,183 |
| Maturities of marketable securities | 28,531 | 31,274 |
| Purchases of property and equipment | 0 | 149 |
| Net cash used in investing activities | -2,618 | -16,058 |
| Proceeds from the exercise of common stock warrants (includes 4,960 in aggregate proceeds from related parties) | 0 | 35,745 |
| Proceeds from exercise of common stock options | 360 | 304 |
| Net cash provided by financing activities | 360 | 36,049 |
| Net decrease in cash and cash equivalents | -11,824 | 5,951 |
| Cash and cash equivalents at beginning of period | 8,740 | - |
| Cash and cash equivalents at end of period | 2,867 | - |
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)